戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uld have implications in the pathogenesis of proliferative vitreoretinopathy.
2  anatomical success, 6 eyes (5.5%) developed proliferative vitreoretinopathy.
3 ith 54.5% of recurrent detachments caused by proliferative vitreoretinopathy.
4  scarring in an experimental rabbit model of proliferative vitreoretinopathy.
5 ges in regeneration and pathologies, such as proliferative vitreoretinopathy.
6 le pharmacological options for prevention of proliferative vitreoretinopathy.
7 n several fibrotic diseases, in RPE cells in proliferative vitreoretinopathy.
8 g this pathway could be useful in preventing proliferative vitreoretinopathy.
9 s that involve RPE dedifferentiation such as proliferative vitreoretinopathy.
10 l diseases, such as diabetic retinopathy and proliferative vitreoretinopathy.
11 ation of fibroproliferative diseases such as proliferative vitreoretinopathy.
12 ted disease progression in a rabbit model of proliferative vitreoretinopathy.
13 l therapy for related human diseases such as proliferative vitreoretinopathy.
14 t of endophthalmitis, retinal detachment and proliferative vitreoretinopathy.
15 atment of retinal detachment associated with proliferative vitreoretinopathy.
16 inopathies, such as diabetic retinopathy and proliferative vitreoretinopathy.
17 y, and in nonvascular retinopathies, such as proliferative vitreoretinopathy.
18 lications for proliferative diseases such as proliferative vitreoretinopathy.
19 of pharmacologic interventions in preventing proliferative vitreoretinopathy?
20 F had lower rates of cataract (0% vs. 4.6%), proliferative vitreoretinopathy (0.1% vs. 2.0%), and ret
21 rrhage (9.1%), epiretinal membrane (45.17%), proliferative vitreoretinopathy (0.98%), and endophthalm
22  inferior quadrant RD (-0.27, P < .001), and proliferative vitreoretinopathy (-0.68, P < .001) correl
23  occlusion with vitreous hemorrhage (1), and proliferative vitreoretinopathy (1).
24 ic, [48.17%] control, P = .0001) and primary proliferative vitreoretinopathy ([15.53%] pandemic, [6.9
25 ual failure of surgery is the development of proliferative vitreoretinopathy, accounting for the fail
26 ogic characteristics of patients who develop proliferative vitreoretinopathy after retinoblastoma tre
27 (RPE) has been implicated in the etiology of proliferative vitreoretinopathy and age-related macular
28 in pathogenesis of such retinal disorders as proliferative vitreoretinopathy and age-related macular
29 on in anomalous reparative processes such as proliferative vitreoretinopathy and as a laboratory tool
30 retinal detachments associated with anterior proliferative vitreoretinopathy and epiciliary membranes
31 several epiretinal membranes associated with proliferative vitreoretinopathy and idiopathic epiretina
32 o significantly more epiretinal membrane and proliferative vitreoretinopathy and lower single-surgery
33 0%) demonstrated redetachment resulting from proliferative vitreoretinopathy and required additional
34 avorable prognosis but may be complicated by proliferative vitreoretinopathy and tractional retinal d
35 ike mass lesion on the optic disc along with proliferative vitreoretinopathy and tractional retinal d
36  NF-kappaB may be a useful strategy to treat proliferative vitreoretinopathy and uveitis, ocular dise
37 teria included recurrent retinal detachment, proliferative vitreoretinopathy, and a lack of postopera
38 inal breaks, failure to reattach the retina, proliferative vitreoretinopathy, and delayed reabsorptio
39 the rate of retinal redetachment by limiting proliferative vitreoretinopathy, and protect against pho
40 comes, development of retinal detachment and proliferative vitreoretinopathy, and the number of secon
41 ns include antimetabolites for modulation of proliferative vitreoretinopathy, antimicrobial agents fo
42 ere uncomplicated (RD unrelated to trauma or proliferative vitreoretinopathy at presentation).
43                                              Proliferative vitreoretinopathy B (retinal wrinkling/ves
44 o have mac-off disease, present with primary proliferative vitreoretinopathy, be lost to follow-up, a
45 = 18.5), presence of a fellow (beta = 14.5), proliferative vitreoretinopathy (beta = 12.8), and great
46                                              Proliferative vitreoretinopathy C (27/100) was clinicall
47  such as primary scleral buckle (4.45/4.60), proliferative vitreoretinopathy detachments (4.57/4.45),
48                                              Proliferative vitreoretinopathy developed in response to
49                                              Proliferative vitreoretinopathy did not develop in salin
50  repair recurrent retinal detachments due to proliferative vitreoretinopathy, focusing on the most re
51 rd PPV (vitreous hemorrhage, dense cataract, proliferative vitreoretinopathy, giant retinal tear, amo
52 ounger than 18 years and those with advanced proliferative vitreoretinopathy, giant retinal tear, tra
53                                    Eyes with proliferative vitreoretinopathy, giant retinal tears, pr
54 cated cataract surgery, former VR surgery or proliferative vitreoretinopathy grade C or higher were e
55   Patients with vision loss for >= 3 months, proliferative vitreoretinopathy grade C or worse, a dema
56                                              Proliferative vitreoretinopathy grade CP incidence was c
57 ature of recurrent retinal detachment due to proliferative vitreoretinopathy has grown concomitantly
58 ithout vascular cell involvement, similar to proliferative vitreoretinopathy in humans.
59 lammatory protein dampens the development of proliferative vitreoretinopathy in mice.
60               The incidence of postoperative proliferative vitreoretinopathy in the PPV/SB group (11.
61                                              Proliferative vitreoretinopathy in turn increases the ri
62 tro model of the later contractile stages of proliferative vitreoretinopathy, interleukin-1 beta (IL-
63                                              Proliferative vitreoretinopathy is a vision-threatening
64                                              Proliferative vitreoretinopathy is caused by the contrac
65  Recurrent retinal detachment complicated by proliferative vitreoretinopathy is now most frequently t
66                                  Significant proliferative vitreoretinopathy, lens status, and macula
67                   Complications consisted of proliferative vitreoretinopathy (n = 13), recurrent neov
68      Exclusion criteria included significant proliferative vitreoretinopathy or previous retinal deta
69 D surgeries, 82 were complicated (history of proliferative vitreoretinopathy or trauma-related RDs at
70 isted of any previous diagnosis of PDR, DME, proliferative vitreoretinopathy, or treatment used in th
71                                    Eyes with proliferative vitreoretinopathy, previous glaucoma surge
72 pes, such as rhegmatogenous RD (RRD) without proliferative vitreoretinopathy (PVR) (n = 30), PVR (n =
73       Eyes that developed a third RRD due to proliferative vitreoretinopathy (PVR) (n = 43) were 110%
74 lens status, tamponading agent, preoperative proliferative vitreoretinopathy (PVR) and axial length (
75 several epiretinal membranes associated with proliferative vitreoretinopathy (PVR) and idiopathic epi
76 ival, and contraction) that are intrinsic to proliferative vitreoretinopathy (PVR) and induce the dis
77 in vitro and in vivo models for experimental proliferative vitreoretinopathy (PVR) and provide a deta
78 ne learning (ML) algorithm design to predict proliferative vitreoretinopathy (PVR) by ophthalmologist
79                                              Proliferative vitreoretinopathy (PVR) exemplifies a dise
80                    During the progression of proliferative vitreoretinopathy (PVR) following ocular t
81 t-derived growth factor (PDGF) contribute to proliferative vitreoretinopathy (PVR) in experimental mo
82 and Galectin-3 levels and the development of proliferative vitreoretinopathy (PVR) in patients with r
83 or (alphaPDGFR) is required for experimental proliferative vitreoretinopathy (PVR) in rabbits.
84                                              Proliferative vitreoretinopathy (PVR) is a blinding cond
85                                              Proliferative vitreoretinopathy (PVR) is a blinding dise
86                                              Proliferative vitreoretinopathy (PVR) is a complication
87                                              Proliferative vitreoretinopathy (PVR) is a complication
88                                              Proliferative vitreoretinopathy (PVR) is a complication
89                                              Proliferative vitreoretinopathy (PVR) is a disorder char
90                                              Proliferative vitreoretinopathy (PVR) is a major cause f
91                                              Proliferative vitreoretinopathy (PVR) is a nonneovascula
92                                              Proliferative vitreoretinopathy (PVR) is a recurring and
93                                              Proliferative vitreoretinopathy (PVR) is a serious compl
94                                              Proliferative vitreoretinopathy (PVR) is a serious probl
95                                              Proliferative vitreoretinopathy (PVR) is characterized b
96                                      Primary proliferative vitreoretinopathy (PVR) is established as
97                                              Proliferative vitreoretinopathy (PVR) is mediated by pro
98                                              Proliferative vitreoretinopathy (PVR) is the leading cau
99                                              Proliferative vitreoretinopathy (PVR) is the leading cau
100                                              Proliferative vitreoretinopathy (PVR) is the major cause
101                                              Proliferative vitreoretinopathy (PVR) is the primary cau
102             TNF-alpha is widely expressed in proliferative vitreoretinopathy (PVR) membranes and is p
103                                              Proliferative vitreoretinopathy (PVR) occurs in approxim
104   To profile vitreous cytokine expression of proliferative vitreoretinopathy (PVR) patients.
105 us from patients with retinal detachment and proliferative vitreoretinopathy (PVR) plus vitreous from
106                                              Proliferative vitreoretinopathy (PVR) remains the most c
107       Retrospective review of three cases of proliferative vitreoretinopathy (PVR) that developed aft
108                                              Proliferative vitreoretinopathy (PVR) thwarts the repair
109 gher level 1 failure rates when grade 0 or B proliferative vitreoretinopathy (PVR) was present and hi
110 macula was attached in 45% eyes, and grade C proliferative vitreoretinopathy (PVR) was present in 12%
111 ibozyme to prevent or inhibit development of proliferative vitreoretinopathy (PVR) was tested in a di
112  28-62 years with primary RRD complicated by proliferative vitreoretinopathy (PVR) with subretinal ba
113 h factor (PDGF) isoforms are associated with proliferative vitreoretinopathy (PVR), a sight-threateni
114 traction by ARPE-19 is an in vitro model for proliferative vitreoretinopathy (PVR), an aberrant wound
115 ermine the role of NF-kappaB in experimental proliferative vitreoretinopathy (PVR), and may offer a n
116 lysis was performed in patients with primary proliferative vitreoretinopathy (PVR), and/or the necess
117 lly advanced often with macular involvement, proliferative vitreoretinopathy (PVR), chronic duration,
118 ence of male sex, foveal detachment, grade C proliferative vitreoretinopathy (PVR), inferior retinal
119 best-corrected visual acuity (BCVA), primary proliferative vitreoretinopathy (PVR), proportion lost t
120                                           In proliferative vitreoretinopathy (PVR), retinal pigment e
121 the environment that drives RPE responses in proliferative vitreoretinopathy (PVR), suggesting that t
122 l detachment with (n = 7) or without (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrha
123 l-thickness macular hole (n = 33), recurrent proliferative vitreoretinopathy (PVR)-related retinal de
124 ery are considered the most common cause for proliferative vitreoretinopathy (PVR).
125 y confer benefits against the development of proliferative vitreoretinopathy (PVR).
126 roliferative diabetic retinopathy (PDR), and proliferative vitreoretinopathy (PVR).
127 of operated eyes) due to variable degrees of proliferative vitreoretinopathy (PVR).
128 mes of vitreoretinal surgery for established proliferative vitreoretinopathy (PVR).
129  and inferior breaks, mostly with associated proliferative vitreoretinopathy (PVR).
130  the repair of retinal detachment related to proliferative vitreoretinopathy (PVR).
131 inal detachment in the context of high-grade proliferative vitreoretinopathy (PVR).
132 n the setting of a blinding condition called proliferative vitreoretinopathy (PVR).
133 proved tyrosine kinase inhibitor, to prevent proliferative vitreoretinopathy (PVR).
134 s age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).
135 bility of fibroblasts to induce experimental proliferative vitreoretinopathy (PVR).
136 sponses in the context of in vitro models of proliferative vitreoretinopathy (PVR).
137 ay of symptom onset, and presence of primary proliferative vitreoretinopathy (PVR).
138 BB (PDGF), and to establish its relevance to proliferative vitreoretinopathy (PVR).
139 h age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).
140 s age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).
141 tor to fibrotic diseases of the eye, such as proliferative vitreoretinopathy (PVR).
142 development of epiretinal membranes found in proliferative vitreoretinopathy (PVR).
143 antial contribution to the events leading to proliferative vitreoretinopathy (PVR).
144 ated in this investigation were: (1) grade B proliferative vitreoretinopathy (PVR; n = 917), (2) grad
145 r surgery (OR, 0.32 [0.11-0.94]; P = 0.039), proliferative vitreoretinopathy (PVR; OR, 0.39 [0.16 - 0
146 io [OR], 7.0), CNV recurrence (OR, 2.6), and proliferative vitreoretinopathy (PVR; OR, 17.6) were sta
147 tachments (pZ3: 87%; aZ3: 71%; P < 0.01) and proliferative vitreoretinopathy (pZ3 66%; aZ3 47%; P < 0
148 er visual outcomes and a lower postoperative proliferative vitreoretinopathy rate.
149                       Here, we show that, in proliferative vitreoretinopathy, recruitment of macropha
150          This intraocular fibrosis, known as proliferative vitreoretinopathy, results in a blinding t
151  patients with retinal detachment (3.65) and proliferative vitreoretinopathy stages A, B, and C (2.06
152                                              Proliferative vitreoretinopathy was a significant progno
153                                              Proliferative vitreoretinopathy was the most common caus

 
Page Top